Abstract 170P
Background
The synergic combination of anti-PD-1/PD-L1 and antiangiogenic agents has exhibited as an encourage treatment pattern in aHCC. Multi-targeted antiangiogenic TKIs, such as lenvatinib and sorafenib, are approved for 1st-line treatment of aHCC. Sintilimab, a novel selective anti-PD-1 monoclonal antibody, has demonstrated encouraging clinical activities in aHCC. The trial aims to explore the safety and efficacy of sintilimab plus anlotinib (a TKI against angiogenesis) in aHCC.
Methods
This is a single-arm phase II study. Pts with aHCC, BCLC stage C or B (not amenable for surgery and chemoembolization), Child-Pugh scores≤7 and ECOG PS ≤ 1 received 1st-line treatment of sintilimab (200mg, iv, D1) plus anlotinib (12mg, po, QD, D1-14) every 3 wks until disease progression or unacceptable toxicity. Primary endpoints were safety and objective response rate (ORR, per RECIST 1.1), and secondary endpoints included disease control rate (DCR), progression free survival (PFS), duration of response (DOR) and overall survival (OS).
Results
As of June 30, 2020, 16 pts with 14 males, median age 56 yrs (range 41-70), BCLC B /C (3/13), and Child-Pugh A/B7(15/1) were enrolled. All pts received at least two cycles of treatments with median cycles 7 (range 2-18). Median follow-up was 5.3 months (range 2.1-13.3). The most common treatment-related adverse events (TRAEs) were grade 1-2 with thrombocytopenia (50%), increased AST (37.5%), ALT (31.3%) and bilirubin (31.3%), decreased neutrophil count (31.3%), leukopenia (25%), hypertension (25%) and hand-foot syndrome (25%). 6 pts experienced manageable grade 3 TRAEs, and no grade 4/5. 7 pts required dose reduction of anlotinib (4 pts to 10 mg and 3 to 8 mg). No treatment withdraw caused by TRAEs. Of 14 evaluable pts, ORR was 42.9% (6/14) with 1 CR and 5 PR. 7 pts were SD, and DCR was 92.9% (13/14). Median DoR was not reached (95%CI: 9.0 months-not reached), and all the responses were ongoing at the data cutoff. 6m-PFS rate was 78.8% (95%CI: 38.1%-94.3%) and mPFS was unreached.
Conclusions
The combination of sintilimab and anlotinib showed promising clinical activities with manageable toxicity for first line treatment of aHCC. Enrolment is on-going to further validate the combination regimen.
Clinical trial identification
NCT04052152.
Editorial acknowledgement
Legal entity responsible for the study
Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University.
Funding
Jiangsu province 333 high level Talents Project; Innovation Funds from Chinese Society of Clinical Oncology Youth Committee. Y-young2019-060; the Advanced Health Talent of Six-One Project of Jiangsu Province. LGY2017069; Joint Research Project by Southeast University and Nanjing Medical University. 3207027381; National Natural Science Foundation of China, 81472306; Key research and development program of Jiangsu Province.BE2016789.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session